Ajanta Pharma Ltd

Ajanta Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ajanta Pharma Ltd

₹ 2,630 -0.95%
08 Jul 1:44 p.m.
ajantapharma.com BSE: 532331 NSE: AJANTPHARM
About

Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).

Key Points

India - Branded Generic business (31% of FY23 revenues)[1]
- Focused on niche and first-to-market drugs in 4 therapeutic areas - cardiology, ophthalmology, dermatology, pain management[2]
- Has an MR strength of ~2800
- Launched 23 products in India in FY22 out of which 6 were first to market.[3] The total product basket comprises 500+ products with 50% being 1st to market[4]

Website BSE NSE
  • Market Cap ₹ 32,849 Cr.
  • Current Price ₹ 2,630
  • High / Low ₹ 3,486 / 2,022
  • Stock P/E 35.8
  • Book Value ₹ 303
  • Dividend Yield 1.34 %
  • ROCE 32.4 %
  • ROE 24.9 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 44.0%

Cons

  • Stock is trading at 8.80 times its book value
  • Promoter holding has decreased over last 3 years: -4.22%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE MidCap Nifty Pharma

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
870 951 938 972 882 1,021 1,028 1,105 1,054 1,145 1,187 1,146 1,170
664 729 742 802 732 750 738 791 776 815 875 825 873
Operating Profit 207 222 196 170 149 271 291 314 278 330 311 321 297
OPM % 24% 23% 21% 17% 17% 27% 28% 28% 26% 29% 26% 28% 25%
29 33 40 35 37 32 21 14 36 26 19 30 18
Interest 7 1 1 3 1 1 2 2 2 1 6 8 6
Depreciation 31 32 33 33 33 33 34 34 34 34 34 36 40
Profit before tax 198 222 203 168 152 269 276 291 278 322 290 307 269
Tax % 24% 21% 23% 20% 20% 23% 29% 28% 27% 24% 25% 24% 16%
151 175 157 135 122 208 195 210 203 246 216 233 225
EPS in Rs 11.80 13.63 12.22 10.50 9.54 16.24 15.24 16.39 15.82 19.68 17.33 18.64 18.03
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,208 1,474 1,749 1,983 2,126 2,055 2,588 2,890 3,341 3,743 4,209 4,648
840 968 1,155 1,292 1,467 1,489 1,904 1,889 2,408 2,934 3,037 3,379
Operating Profit 369 505 594 691 658 567 683 1,001 933 808 1,172 1,269
OPM % 31% 34% 34% 35% 31% 28% 26% 35% 28% 22% 28% 27%
14 8 14 20 24 21 88 24 112 74 85 85
Interest 9 6 5 1 0 1 12 8 10 6 7 21
Depreciation 44 52 44 61 60 72 96 116 125 131 135 144
Profit before tax 330 456 559 648 623 514 664 900 909 745 1,114 1,189
Tax % 29% 32% 26% 22% 25% 25% 30% 27% 22% 21% 27% 23%
234 310 416 507 469 387 468 654 713 588 816 920
EPS in Rs 17.75 23.47 31.49 38.40 35.50 29.56 35.73 50.38 55.63 45.89 63.70 73.68
Dividend Payout % 15% 17% 17% 23% -0% 20% 24% 13% 11% 15% 79% 38%
Compounded Sales Growth
10 Years: 12%
5 Years: 12%
3 Years: 12%
TTM: 10%
Compounded Profit Growth
10 Years: 11%
5 Years: 14%
3 Years: 9%
TTM: 13%
Stock Price CAGR
10 Years: 10%
5 Years: 23%
3 Years: 30%
1 Year: 16%
Return on Equity
10 Years: 24%
5 Years: 22%
3 Years: 22%
Last Year: 25%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 18 18 18 18 18 18 18 17 17 25 25 25
Reserves 576 823 1,173 1,550 2,024 2,228 2,581 2,978 3,247 3,363 3,542 3,765
130 72 81 1 2 36 75 31 25 36 35 47
226 233 207 254 383 383 619 702 711 1,159 927 1,067
Total Liabilities 949 1,146 1,479 1,823 2,426 2,664 3,293 3,729 4,000 4,582 4,530 4,904
279 288 451 589 1,053 1,178 1,472 1,541 1,512 1,496 1,479 1,762
CWIP 94 170 240 339 61 262 132 108 153 209 256 176
Investments 63 60 86 182 190 78 79 176 147 535 349 464
513 629 703 713 1,122 1,147 1,610 1,904 2,188 2,341 2,446 2,502
Total Assets 949 1,146 1,479 1,823 2,426 2,664 3,293 3,729 4,000 4,582 4,530 4,904

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
212 279 326 609 281 375 457 576 562 792 785 1,157
-188 -158 -209 -383 -256 -223 -224 -282 -74 -560 65 -377
-20 -105 -117 -202 -0 -147 -129 -318 -460 -108 -1,051 -733
Net Cash Flow 4 16 -0 24 25 4 104 -24 28 124 -201 47

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 61 64 78 59 79 82 109 93 111 103 108 93
Inventory Days 164 159 180 186 315 415 276 434 347 283 283 308
Days Payable 132 109 128 157 224 214 202 212 143 147 159 155
Cash Conversion Cycle 94 114 130 88 170 282 184 315 315 240 233 246
Working Capital Days 57 61 90 65 103 119 116 127 141 84 120 98
ROCE % 55% 57% 52% 46% 34% 24% 27% 32% 29% 23% 32% 32%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
70.48% 70.48% 66.11% 66.11% 66.22% 66.22% 66.22% 66.22% 66.27% 66.26% 66.26% 66.26%
8.30% 8.23% 10.07% 10.00% 10.19% 9.99% 9.11% 8.54% 8.36% 9.11% 9.26% 8.86%
12.46% 12.68% 15.37% 15.52% 15.36% 15.60% 16.67% 17.48% 17.41% 17.09% 17.02% 17.48%
0.45% 0.45% 0.45% 0.45% 0.46% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01%
8.31% 8.15% 8.00% 7.91% 7.78% 8.21% 8.00% 7.76% 7.94% 7.51% 7.45% 7.38%
No. of Shareholders 64,44562,04859,79883,54954,87456,27754,35155,48870,31664,31566,89670,827

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls